Month: June 2024

Emmanuel Ladent, CEO, CARBIOS (fifth from right) and Zhu GuoYang, President of Zhink Group (fourth from right)Emmanuel Ladent, CEO, CARBIOS (fifth from right) and Zhu GuoYang, President of Zhink Group (fourth from right) surrounded by their teams at Zhink Group’s Headquarters in Hangzhou, China This partnership would allow Zhink Group to meet its leadership ambitions through increased recycled PET capacities and sustainable competitiveness by offering recycled PET from enzymatic recycling This agreement confirms strong traction for CARBIOS biorecycling technology in China, the world’s leading PET producer Based in China, the future plant will depolymerize minimum 50k tons of PET waste per year, with potential to expand capacities, to serve regional and global packaging and textile markets  Clermont-Ferrand (France) and Hangzhou...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES (Note: All dollar amounts in this news release are expressed in U.S. dollars except as otherwise noted.) TORONTO, June 26, 2024 (GLOBE NEWSWIRE) —  Fairfax India Holdings Corporation (“Fairfax India” or the “Company”) (TSX: FIH.U) announces that its wholly-owned subsidiary, FIH Mauritius Investments Ltd has sold a 9.7% equity interest in CSB Bank Limited (“CSB Bank”) over the stock exchange in India (the “CSB Bank Sale”) for gross proceeds of INR 5.9 billion (approximately $70 million at current exchange rates) in order to comply with the dilution requirements of the Reserve Bank of India (“RBI”), the banking regulator in India. As a result of the CSB Bank Sale, Fairfax India’s share ownership in CSB Bank will be reduced to 40% and Fairfax India...

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) — Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a price to the public of $6.50 per share. All of the shares are to be sold by Recursion. In addition, Recursion has granted the underwriters a 30-day option to purchase up to an additional 4,615,384 shares of its Class A common stock.  Before deducting the underwriting discounts and commissions and estimated offering expenses, Recursion expects to receive total gross proceeds of approximately $200 million, assuming no exercise of the underwriters’ option to purchase additional shares. The offering is expected to close...

BEND, Ore., June 26, 2024 (GLOBE NEWSWIRE) — BranchOut Food Inc. (NASDAQ: BOF) (“BranchOut” or the “Company”), a leading food technology company specializing in dehydrated fruit and vegetable-based products, today announced the pricing of its underwritten public offering of 1,750,000 shares of common stock at a public offering price of $0.80 per share. The gross proceeds from the offering, before underwriting discounts and commissions and estimated offering expenses payable by the Company, are expected to be approximately $1,400,000. In addition, the Company has granted the underwriters a 45-day option to purchase up to 262,500 additional shares of common stock at the public offering price, less the underwriting discounts. The offering is expected to close on or about June 28, 2024, subject to the satisfaction of customary closing...

Additional payments are expected to follow MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, is pleased to provide additional information in response to investor questions regarding receipt of the CAD$4.1 million payment announced earlier today. As previously announced, PyroGenesis contracted with Drosrite International LLC, which was in turn contracted by Radian Oil and Gas Services Company for an order of seven (7) Drosrite™ aluminum dross recovery systems pursuant to a CAD$25 million contract. The...

VANCOUVER, British Columbia, June 26, 2024 (GLOBE NEWSWIRE) — ELSE NUTRITION HOLDINGS INC. (BABY) (BABYF) (0YL.F) (“Else” or the “Company”), the Plant-Based baby, toddler, and children nutrition company, today announced that it has entered into an agreement with a single, healthcare-focused institutional investor for the purchase and sale of 13,245,033 Units (the “Units”) of the Company (collectively, the “Offering”), which will be sold at an issue price of US$0.151 per Unit (the “Issue Price”), for aggregate gross proceeds of US$2 million. The Offering is scheduled to close on, or shortly after, June 28, 2024, and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the Toronto Stock Exchange. The Company plans to use the net proceeds...

Tokyo, Japan and Cambridge, UK, 27 June 2024 – Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million to Nxera. Nxera and AbbVie entered into this multi-target collaboration in 2022 to leverage Nxera’s NxWave™ platform to discover, develop and commercialize new medicines targeting novel G protein-coupled receptor (GPCR) targets associated with neurological disease. Under the terms of the agreement, Nxera is eligible to receive up to US$40 million in near-term research milestones, as well as further potential option, development and commercial milestones totalling up to US$1.2 billion, plus tiered royalties on global sales. Stacey Southall, VP Platform...

Company AnnouncementApproval based on results from Phase 1/2 EPCORE® NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients with challenging-to-treat R/R FL EPKINLY offers an off-the-shelf, T-cell engaging treatment option that enables treatment across practice settings to address high clinical need EPKINLY is the first and only bispecific antibody approved in the U.S. to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapyCOPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more...

CALGARY, Alberta, June 26, 2024 (GLOBE NEWSWIRE) — Condor Energies Inc. (“Condor” or the “Company”) (TSX:CDR), a Canadian based energy transition company is pleased to announce the initiation of a multi-well workover campaign for the eight gas-condensate fields it operates in Uzbekistan (the “Project”). This initial workover campaign includes installing proven artificial lift equipment to yield higher gas flow rates and increase well uptime, perforating newly identified pay intervals, performing downhole stimulation treatments, and isolating identified water intervals. With over 100 wells associated with the Project, both existing and shut-in wells will continue to be evaluated for optimization opportunities. The Company has also started construction of the first in-line flow separation unit, which separates water from the gas...

BRISBANE, Australia, June 27, 2024 (GLOBE NEWSWIRE) — NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or “the Company”), a leading battery materials and technology company, today announced it has been granted a patent for its proprietary all-dry, zero-waste cathode synthesis technology in Japan. This patent (Patent JP7504195) furthers NOVONIX’s position as a leading provider of innovative technologies serving the electric vehicle and energy storage sectors by utilizing its all-dry, zero-waste cathode processing to produce high-quality single-crystal NMC powders. The Company currently has 10 families of cathode process patent applications in various stages of examination across different jurisdictions. Dr. Chris Burns, CEO of NOVONIX, said, “NOVONIX’s cathode process is a groundbreaking innovation that offers a transformative...